The sudden explosion in CBD popularity across the U.S. since the passage of the 2018 Farm Bill has seen the Food & Drug Administration (FDA) scrambling to keep up with new product launches while crafting an overall regulatory policy towards the hemp-derived substance.
Today the FDA issued a consumer update warning it has not concluded CBD is safe in food meant for human or animal consumption, and raising concerns about potential health problems tied to cannabidiol usage that haven’t yet been fully studied.
Warning letters were additionally sent to 15 companies letting them know they are in violation of the Federal Food, Drug, and Cosmetic Act by selling CBD products marketed either as dietary supplements or as therapeutic treatments for diseases.
Back in July, Curaleaf Holdings was also warned by the FDA to drop advertising indicating CBD products may be treating or preventing specific diseases. The companies that were notified of violations today include:
- Apex Hemp Oil LLC
- Bella Rose Labs
- Daddy Burt LLC
- Healthy Hemp Strategies LLC d/b/a Curapure
- Infinite Product Company LLLP d/b/a Infinite CBD
- Koi CBD LLC
- Noli Oil
- Natural Native LLC
- Organix Industries Inc. d/b/a Plant Organix
- Pink Collections Inc.
- Private I Salon LLC
- Red Pill Medical Inc
- Sabai Ventures Ltd.
- Sunflora Inc / Your CBD Store
- Whole Leaf Organics LLC
Noting the skyrocketing popularity and overall public interest in CBD products, FDA Principal Deputy Commissioner Amy Abernethy commented on the consumer update and company warning letters:
Some CBD products have also taken a hit recently due to a vape-related health scare as dozens of cases of lung disease have been tied to vaping in the U.S.
Although the Centers For Disease Control has stated the main contributing cause at this point appears to be vitamin E acetate found in unlicensed, black market THC products, that hasn’t stopped some states from enacting temporary bans on all flavoured vaping.